Stockreport
Antiva Biosciences Announces Formation of Scientific and Development Advisory Board [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
REDWOOD CITY, Calif. June 13, 2024 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of high-risk infections and pre-cancerous lesions caused by human papilloma virus (HPV) in women, today announced the formation of a scientific and development advisory board featuring distinguished thought leaders from both academia and industry with clinical expertise spanning the fields of women's health and virology. Additionally, several inaugural members of this advisory board possess deep experience in drug discovery and development, including launch and commercialization of novel therapeutics. The newly formed scientific and development advisory board will provide Antiva with key scientific and clinical guidance to support its continued development of ABI-2280, a topical treatment for high-grade cervical intraepithelial neoplasia (HSIL, CIN 2,3) and for women with high-risk HPV infection. "We have been fortunate to estab
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences stock jumps on HIV treatment trial success [Yahoo! Finance Canada][Yahoo! Finance Canada]
- Gilead Stock Surges on Strong Results in HIV Drug Study [Yahoo! Finance][Yahoo! Finance]
- Nvidia Reverses Lower From New High; Is The Stock A Buy Now? [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences, Inc. (NASDAQ: GILD) had its "neutral" rating re-affirmed by analysts at Robert W. Baird. They now have a $80.00 price target on the stock.[MarketBeat]
- Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- GILD's page on the SEC website
- More